IL6 and non-small cell lung carcinoma: Interleukin-6 (IL6) is an inflammation-associated cytokine known to be predictive of poor disease-specific outcomes when upregulated in the serum of patients with solid tumours such as non-small cell lung cancer, prostate cancer and CRC [2,3,4,5].